Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Researchers evaluated barriers to anti-CD19+ CAR T-cell therapy for patients with non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. They found that 41% of community patients with NHL were unable to access timely CAR T-cell therapy. Attrition from disease-related factors was one of the main causes of ineligibility. They concluded that reducing time to apheresis, early referral, and more attention to salvage and bridging strategies are steps that must be taken to combat these access barriers.